This review addresses current changes in the approach to treating patients with multiple sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment efficacy (LETA) at onset with subsequent escalation has been challenged by new data suggesting that MS patients derive greater benefit when therapy is initiated with high-efficacy treatment agents (HETA). Several recent studies compared treatment efficacy and safety of early administration of HETA versus LETA. The results of randomized, double blind, phase III studies with LETA as a control arm and population-based larger and longer studies using propensity scoring, marginal structural modeling and weighted cumulative exposure analysis support the benefit of early treatment with HETA. Patients initiating their treatment with HETA, regardless of prognostic factors and MRI burden at baseline, showed significantly lower annualized relapse rate (ARR) and reduced disability progression in follow-up periods of up to 10-15 years. Moreover, the safety profile of recently approved HETA ameliorates concerns about off-target effects associated with a number of earlier high-efficacy drugs. Patient perception has also changed with an increasing preference for medication profiles that both improve symptoms and prevent disease progression. Accumulating data from randomized studies and the results of large population-based studies demonstrating short-term and longer-term patient benefits support the view that HETA should be more widely used. The adoption of early treatment with HETA capitalizes on a window of opportunity for anti-inflammatory drugs to maximally impact disease pathology and heralds a sea change in clinical practice toward pro-active management and away from a philosophy routed in generating clinical benefit as a consequence of treatment failure.

Brain and Mind Centre University of Sydney Sydney Australia

Center of Neurology Lodz Poland

Department of Neurology Heinrich Heine University Düsseldorf Germany

Department of Neurology Medical University of Vienna Vienna Austria

Department of Neurology Palacky University Olomouc Olomouc Czech Republic

Department of Neurology University of Warmia and Mazury 30 Warszawska Ave 10 082 Olsztyn Poland

Department of Neurology Weill Neurosciences Institute UCSF San Francisco USA

Faculty of Brain Sciences University College London London UK

000      

00000naa a2200000 a 4500

001      

bmc24007819

003      

CZ-PrNML

005      

20240423160309.0

007      

ta

008      

240412s2024 gw f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s00415-023-11969-8 $2 doi

035    __

$a (PubMed)37851189

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a gw

100    1_

$a Selmaj, Krzysztof $u Department of Neurology, University of Warmia and Mazury, 30 Warszawska Ave, 10-082, Olsztyn, Poland. kselmaj@gmail.com $u Center of Neurology, Lodz, Poland. kselmaj@gmail.com

245    10

$a Multiple sclerosis: time for early treatment with high-efficacy drugs / $c K. Selmaj, BAC. Cree, M. Barnett, A. Thompson, HP. Hartung

520    9_

$a This review addresses current changes in the approach to treating patients with multiple sclerosis (MS). The widely practiced approach of utilizing agents with lower treatment efficacy (LETA) at onset with subsequent escalation has been challenged by new data suggesting that MS patients derive greater benefit when therapy is initiated with high-efficacy treatment agents (HETA). Several recent studies compared treatment efficacy and safety of early administration of HETA versus LETA. The results of randomized, double blind, phase III studies with LETA as a control arm and population-based larger and longer studies using propensity scoring, marginal structural modeling and weighted cumulative exposure analysis support the benefit of early treatment with HETA. Patients initiating their treatment with HETA, regardless of prognostic factors and MRI burden at baseline, showed significantly lower annualized relapse rate (ARR) and reduced disability progression in follow-up periods of up to 10-15 years. Moreover, the safety profile of recently approved HETA ameliorates concerns about off-target effects associated with a number of earlier high-efficacy drugs. Patient perception has also changed with an increasing preference for medication profiles that both improve symptoms and prevent disease progression. Accumulating data from randomized studies and the results of large population-based studies demonstrating short-term and longer-term patient benefits support the view that HETA should be more widely used. The adoption of early treatment with HETA capitalizes on a window of opportunity for anti-inflammatory drugs to maximally impact disease pathology and heralds a sea change in clinical practice toward pro-active management and away from a philosophy routed in generating clinical benefit as a consequence of treatment failure.

650    _2

$a lidé $7 D006801

650    12

$a roztroušená skleróza $x diagnostické zobrazování $x farmakoterapie $7 D009103

650    _2

$a léčivé přípravky $7 D004364

650    _2

$a výsledek terapie $7 D016896

650    12

$a relabující-remitující roztroušená skleróza $x farmakoterapie $7 D020529

650    _2

$a randomizované kontrolované studie jako téma $7 D016032

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

700    1_

$a Cree, Bruce A C $u Department of Neurology, Weill Neurosciences Institute, UCSF, San Francisco, USA

700    1_

$a Barnett, Michael $u Brain and Mind Centre, University of Sydney, Sydney, Australia

700    1_

$a Thompson, Alan $u Faculty of Brain Sciences, University College, London, London, UK

700    1_

$a Hartung, Hans-Peter $u Brain and Mind Centre, University of Sydney, Sydney, Australia $u Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany $u Department of Neurology, Medical University of Vienna, Vienna, Austria $u Department of Neurology, Palacky University, Olomouc, Olomouc, Czech Republic

773    0_

$w MED00002835 $t Journal of neurology $x 1432-1459 $g Roč. 271, č. 1 (2024), s. 105-115

856    41

$u https://pubmed.ncbi.nlm.nih.gov/37851189 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y - $z 0

990    __

$a 20240412 $b ABA008

991    __

$a 20240423160305 $b ABA008

999    __

$a ok $b bmc $g 2081674 $s 1217586

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2024 $b 271 $c 1 $d 105-115 $e 20231018 $i 1432-1459 $m Journal of neurology $n J Neurol $x MED00002835

LZP    __

$a Pubmed-20240412